GeneNews is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases.
Latest News: Colon Cancer On Rise In Young Adults
ColonSentry® Can Asses Your Risk and Provide Actionable Clinical Information for Doctors and Patients
ColonSentry® is a blood-based test that can assess a patient's current risk of having colorectal cancer. The test is not considered a replacement for colonoscopy, but rather a more convenient step in determining early warning signs of colon cancer. ColonSentry does not require patients to provide a stool sample, nor does it require any dietary restrictions like fasting or refraining from certain foods or medications prior to taking the test. The ColonSentry test is easy to perform and blood can be drawn at the same time as other tests.
Our ColonSentry Test Is Now Available throughout U.S.
In The News
GeneNews Acquires Full Control of Innovative Diagnostic Laboratory
TORONTO, March 04, 2016 (GLOBE NEWSWIRE) -- GeneNews Limited (“GeneNews” or the “Company”) (TSX:GEN) today announced that it has entered into a Unit Purchase Agreement (the “Purchasing Agreement”) with Cobalt Healthcare Consultants, Inc. (“Cobalt”), pursuant to which GeneNews’ wholly-owned subsidiary, GeneNews (USA), Inc., will acquire Cobalt’s fifty percent (50%) ownership interest in the Innovative Diagnostic Laboratory, LLP (“IDL”) joint-venture. Once concluded, GeneNews will have full ownership of IDL. Read More